PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM CELL TRANSPLANT

3 期 AML：柔红霉素剂量加强

• 批准号: 7625776
• 负责人: Witold B. Rybka
• 金额: $ 3.01万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625776
• 关键词: Autologous; Computer Retrieval of Information on Scientific Projects Database; Daunorubicin; Disease-Free Survival; Dose; Funding; Gemtuzumab Ozogamicin; Grant; Institution; Peripheral Blood Stem Cell; Phase; Protocols documentation; Research; Research Personnel; Resources; Source; Stem cell transplant; Transplantation; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this protocol is to compare disease-free survival (DFS) between two consolidation regimes: Gemtuzumab-ozogamicin followed by autologous peripheral blood stem cell (PBSC) transplant or directly to autologous transplant.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本方案的主要目的是比较两种巩固方案之间的无病生存期（DFS）：吉妥珠单抗-奥佐霉素，随后自体外周血干细胞（PBSC）移植或直接自体移植。